Biotech
Lyell Immunopharma
Lyell Immunopharma raises $425M Series C at $1.4B valuation
$425M
Total Raised
Series C
Latest Round
2018
Founded
300+
Employees
201 Haskins Way, South San Francisco, CA 94080
1 min read
Quick Facts
Valuation
$1.4B
Latest Round Size
$425M
Latest Round Date
March 2024
Lyell Immunopharma: Series C Funding Round
Lyell Immunopharma has successfully raised $425M in Series C funding, reaching a valuation of $1.4B.
Company Overview
T-cell reprogramming for solid tumors
Funding Details
The Series C round was led by GV, with participation from F-Prime Capital, Bain Capital Life Sciences, Patient Square Capital, Bristol Myers Squibb.
Company Information
- Headquarters: 201 Haskins Way, South San Francisco, CA 94080
- Founded: 2018
- Employees: 300+
- Category: Biotech
Investment
Lyell Immunopharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- GV: Verified investor in Series C
- F-Prime Capital: Verified investor in Series C
- Bain Capital Life Sciences: Verified investor in Series C
- Patient Square Capital: Verified investor in Series C
- Bristol Myers Squibb: Verified investor in Series C
Key Investors
GV
Lead Investor
Verified investor in Series C
F-Prime Capital
Investor
Verified investor in Series C
Bain Capital Life Sciences
Investor
Verified investor in Series C
Patient Square Capital
Investor
Verified investor in Series C
Bristol Myers Squibb
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M